CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies

Daniel Morillo; Gala Vega; Victor Moreno

doi:10.18632/oncotarget.28473

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies

Daniel Morillo, Gala Vega and Victor Moreno _

PDF | Full Text | How to cite | Press Release

Oncotarget. 2023; 14:749-752. https://doi.org/10.18632/oncotarget.28473

Metrics: PDF 533 views | Full Text 1883 views | ?

Abstract

Daniel Morillo1, Gala Vega1 and Victor Moreno2

1 Division of Hematology, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain

2 Division of Oncology, START Madrid-FJD, Hospital Fundación Jiménez Díaz, Madrid, Spain

Correspondence to:

Victor Moreno,

email:

[email protected]

Keywords: cyclin-dependent kinases (CDK); CDK9; hematological malignancies

Received: April 18, 2023 Accepted: June 21, 2023 Published: August 07, 2023

Copyright: © 2023 Morillo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Most hematological malignancies are characterized by overexpression of certain cancer promoting genes, such as MYC, MCL1 and cyclin D1. Preclinical studies in animal models have shown that CDK9 inhibitors supress the transcription of these anti-apoptotic and pro-survival proteins, and suggest their potential synergism with other drugs. In its first in-human trial, enitociclib demonstrated clinical activity in a small cohort of patients with high grade B lymphoma with MYC and BCL2 and/or BCL6 rearrangements, inducing complete responses in 2 of 7 subjects (29%) in monotherapy. These data suggest CDK9 inhibitors could play a role in the treatment of hematological diseases and could be a great ally when combined with other therapeutic approaches.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28473

Publication Alerts

Research Perspectives:

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies

Abstract